ASP3652 + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cystitis, Interstitial

Conditions

Cystitis, Interstitial, Urinary Bladder Disease, Pain, Urologic Diseases

Trial Timeline

May 31, 2012 → Mar 18, 2014

NCT ID

NCT01613586

About ASP3652 + Placebo

ASP3652 + Placebo is a phase 2 stage product being developed by Astellas Pharma for Cystitis, Interstitial. The current trial status is completed. This product is registered under clinical trial identifier NCT01613586. Target conditions include Cystitis, Interstitial, Urinary Bladder Disease, Pain.

What happened to similar drugs?

2 of 5 similar drugs in Cystitis, Interstitial were approved

Approved (2) Terminated (2) Active (2)

❌Mirabegron + PlaceboAstellas PharmaPhase 3

✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved

✅RocuroniumMerckApproved

🔄Certolizumab pegol + PlaceboUCBPhase 3

🔄moxifloxacinBayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01815684	Phase 1	Completed	Aug 1, 2012	Dec 1, 2012	Pharmacokinetics
NCT01613586	Phase 2	Completed	May 31, 2012	Mar 18, 2014	Cystitis, Interstitial
NCT01391338	Phase 2	Completed	Jun 1, 2011	Feb 1, 2013	Chronic Abacterial Prostatitis
NCT02243657	Phase 1	Completed	May 1, 2009	May 1, 2010	Healthy Subjects

Competing Products

19 competing products in Cystitis, Interstitial

See all competitors

Product	Company	Stage	Hype Score
Ferumoxytol + Gadobutrol	Lipella Pharmaceuticals	Phase 1	19
LP-10	Lipella Pharmaceuticals	Phase 2	25
LP-08 80mg + Normal saline + LP-08 20mg	Lipella Pharmaceuticals	Phase 2	25
Mirabegron + Placebo	Astellas Pharma	Phase 3	32
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	42
Placebo + JNJ-42160443	Johnson & Johnson	Phase 2	27
Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg	Johnson & Johnson	Approved	35
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	35
Rocuronium	Merck	Approved	43
Cidofovir	Gilead Sciences	Pre-clinical	18
PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685	Pfizer	Phase 2	35
Tanezumab + Tanezumab + Tanezumab + Tanezumab	Pfizer	Phase 2	27
ERB-041	Pfizer	Pre-clinical	18
PF-04383119 + Placebo	Pfizer	Phase 2	35
Certolizumab pegol + Placebo	UCB	Phase 3	40
moxifloxacin	Bayer	Phase 3	37
Cipro (Ciprofloxacin, BAYQ3939)	Bayer	Pre-clinical	23
IW-3300 rectal foam + Placebo	Ironwood Pharmaceuticals	Phase 2	21
MN-001 BID + MN-001 + Placebo	MediciNova	Phase 2	25